<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-211 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-211</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-211</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-5.html">extraction-schema-5</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing East Asian and non-Asian populations, including frequencies, patient characteristics, environmental factors, and proposed explanations for ethnic differences.</div>
                <p><strong>Paper ID:</strong> paper-252547209</p>
                <p><strong>Paper Title:</strong> Genomic landscape of lung adenocarcinomas in different races</p>
                <p><strong>Paper Abstract:</strong> Background Lung adenocarcinoma is a molecularly heterogeneous disease. Several studies, including The Cancer Genome Atlas Research Network (TCGA) and Lung Cancer Mutation Consortium (LCMC), explored the genetic alterations among different ethnic groups. However, minority groups are often under-represented in these relevant studies and the genomic alterations among racial groups are not fully understood. Methods We analyze genomic characteristics among racial groups to understand the diversities and their impact on clinical outcomes. Results Native Americans had significantly higher rates of insertions and deletions than other races (P<0.001). Among patients with lung adenocarcinomas, EGFR and KRAS were the highest discrepancy genes in the different racial groups (P<0.001). The EGFR exon 21 L858R point mutation was three times higher in Asians than in all other races (P<0.001). Asians, Whites, and Blacks had 4.7%, 3.1%, and 1.8% ALK rearrangement, respectively (P<0.001). White patients had the highest rates of reported KRAS G12C (15.51%) than other races (P<0.001). Whites (17.2%), Blacks (15.1%), and Other (15.7%) had higher rates of STK11 mutation than Asians (3.94%) (P<0.001). RET rearrangement and ERBB2 amplification were more common in Asian patients than in Other racial groups. Apart from point mutations, structural variations, and fusion genes, we identified a significant amount of copy number alterations in each race. Conclusions The tumor genomic landscape is significantly distinct in different races. This data would shed light on the understanding of molecular alterations and their impacts on clinical management in different lung cancer patients.</p>
                <p><strong>Cost:</strong> 0.01</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e211.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e211.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing East Asian and non-Asian populations, including frequencies, patient characteristics, environmental factors, and proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR prevalence (GENIE)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>EGFR mutation prevalence in lung adenocarcinoma across races (AACR GENIE v8.0 analysis)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Reported frequencies and subtype distribution of somatic EGFR alterations in metastatic lung adenocarcinoma across self-reported racial groups from the AACR GENIE v8.0 dataset, with comparisons between Asians, Whites, Blacks, Native Americans, and Other.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Genomic landscape of lung adenocarcinomas in different races</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>6,238 patients (7,023 samples) with lung adenocarcinoma from AACR GENIE v8.0 who had comprehensive targeted sequencing (gene panel >=275). Racial composition: 84.89% White, 8.64% Asian, 4.81% Black, 0.16% Native American, 1.50% Other; samples primarily from major U.S. cancer centers (DFCI, MSK, JHU, Wake Forest, etc.).</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_type</strong></td>
                            <td>EGFR exon 19 deletions, exon 21 L858R point mutation, exon 18 mutations, exon 20 mutations (including insertions), T790M; analysis considered EGFR exons 1-28 and categorized TKI-sensitive vs drug-resistant mutations.</td>
                        </tr>
                        <tr>
                            <td><strong>mutation_frequency_asian</strong></td>
                            <td>61.75% overall EGFR alteration rate in Asians; 27.81% exon 19 deletions; 27.21% exon 21 L858R; 10.45% T790M. (All percentages reported from AACR GENIE cohort in this paper.)</td>
                        </tr>
                        <tr>
                            <td><strong>mutation_frequency_non_asian</strong></td>
                            <td>Whites: 22.56% overall EGFR alteration; Whites specifically 9.18% exon 19 deletions; Blacks: 33.67% overall EGFR alteration; Native Americans: 30.00% overall EGFR alteration and 27.27% exon 19 deletions (note small Native American sample size); Other: 26.60% overall EGFR alteration. (All percentages reported in this paper.)</td>
                        </tr>
                        <tr>
                            <td><strong>has_comparative_ethnic_data</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>patient_smoking_status</strong></td>
                            <td>Not available in GENIE for this cohort; authors note smoking history is missing and may contribute to observed differences (smoking status unclear/missing).</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>Lung adenocarcinoma (LUAD) â€” the cohort consists of LUAD samples only.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td>Smoking is discussed as a likely contributor (association of C>A transversions with smoking; C>T transitions enriched in never-smokers), but direct smoking data were not available. Authors mention socioeconomic factors, prior treatment, and environmental/lifestyle factors in general as possible contributors, but no specific environmental exposures (e.g., air pollution, cooking fumes) are measured or reported in this dataset.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factors</strong></td>
                            <td>Authors note higher copy-number amplifications in Asians at 7p11.2 (EGFR locus) and other loci (5p15.33, 12q15, 14q13.3) that could contribute; they also discuss the potential role of germline ancestry/ancestry-informative markers (AIM) vs self-reported race and recommend AIM-based studies to resolve genetic contributions.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Multiple, non-mutually exclusive hypotheses: (1) differing smoking prevalence and mutational signatures by race (smoking-related C>A transversions vs C>T in never-smokers) leading to different driver spectra; (2) germline/ancestral predisposition and somatic CNA differences (e.g., EGFR locus amplification at 7p11.2) increasing EGFR alterations in Asians; (3) differences in tumor stage, prior therapy, and sample selection across datasets; (4) lifestyle/environmental exposures and socioeconomic/healthcare access influencing observed frequencies; (5) lower STK11 mutation frequency in Asians possibly modulating immune environment and outcomes. The paper does not claim a definitive mechanism but presents these as plausible explanations.</td>
                        </tr>
                        <tr>
                            <td><strong>odds_ratio_or_risk</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>confounding_factors</strong></td>
                            <td>Missing smoking history and prior treatment data in GENIE; differences in sequencing platforms and panel sizes across studies; stage differences (GENIE enriched for metastatic samples vs TCGA early-stage); sample size disparities (small Native American group); referral/selection bias from major cancer centers; use of self-reported race rather than genetic ancestry (possible admixture), and socioeconomic/treatment access differences.</td>
                        </tr>
                        <tr>
                            <td><strong>key_findings</strong></td>
                            <td>This large multi-center targeted-sequencing analysis shows markedly higher prevalence of EGFR alterations in self-reported Asian LUAD patients (61.75% overall), driven mainly by exon 19 deletions (~27.8%) and exon 21 L858R (~27.2%), compared with substantially lower rates in Whites (22.56% overall; 9.18% exon 19 deletions) and intermediate rates in Blacks (33.67%) and Other groups. A high fraction of EGFR alterations were TKI-sensitive (74.14% of EGFR mutations overall) while T790M (resistance-associated) comprised 10.68% overall and was highest in Asians (10.45%). The authors emphasize that ethnic differences are robust in this dataset but note that missing smoking/treatment data, self-reported race, and selection biases prevent definitive causal attribution; they propose genetic (CNA and ancestry) and environmental/lifestyle (including smoking) explanations and call for AIM-based and better-annotated studies.</td>
                        </tr>
                        <tr>
                            <td><strong>additional_notes</strong></td>
                            <td>The paper also cites prior literature reporting ~40-60% EGFR mutation rates in Asians (references 17-19) and a reported 35% frequency in Asian smokers (reference 20), which the authors mention in the Introduction; these prior numbers are summarized by the authors but derive from other studies.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Genomic landscape of lung adenocarcinoma in East asians <em>(Rating: 2)</em></li>
                <li>Molecular epidemiology of EGFR mutations in Asian patients with advanced non-Small-Cell lung cancer of adenocarcinoma histology -mainland China subset analysis of the PIONEER study <em>(Rating: 2)</em></li>
                <li>Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the lung cancer mutation consortium <em>(Rating: 2)</em></li>
                <li>EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy <em>(Rating: 1)</em></li>
                <li>Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>